Global Cancer Immunotherapy Market Outlook 2020

June 2015 | 2600 pages | ID: G95FBBB1B98EN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Immune system is an intricate network of various tissues, organs and cell that prevents the attack by infectious agents. It prevents the growth and development of pathogens in body that may cause disease development. Wide array of potential disease causing microorganism like bacteria, fungus and virus are identified and eliminated in the body. Immune system also has ability to identify self from foreign cells due to which transplant rejection is observed. It has capability to generate memory that helps in providing long-term memory. Dead and abnormal cell are removed from the body that may hinder the normal functioning of cellular processes. It could also be trained to identify and eliminate particular cells from the body by giving suitable cues. Investigators have utilized this property of immune system to treat diseases by modulating immune responses. Investigators have extended this modality for preventing cancer progression and proliferation by stimulating patients’ immune system.

Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects.

Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years.

Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts.

Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data.

New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future.

Cancer Immunotherapies Included in Report:

Adoptive Cell Transfer , GM-CSF, Immune Checkpoint Inhibitors, Immunomodulators, Interleukins, Interferon, Monoclonal Antibodies, Vaccines

'Global Cancer Immunotherapy Market Outlook 2020' Report Highlight:

• Introduction & Classification of Cancer Immunotherapy
• Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
• Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
• Global Cancer Immunotherapy Pipeline: 1834 Drugs
• Marketed Cancer Immunotherapies: 113 Drugs
• Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
• Cancer Vaccines Pipeline: 312 Vaccines
• Marketed Cancer mAb: 36 mAb
• Marketed Cancer Vaccines: 12 Vaccines

Contents

1. INTRODUCTION TO CANCER IMMUNOTHERAPY

2. CLASSIFICATION OF CANCER IMMUNOTHERAPY

2.1 Specific Cancer Immunotherapy
2.2 Non-Specific Cancer Immunotherapy

3. CANCER IMMUNOTHERAPY BY VACCINES

3.1 Introduction
3.2 Mechanism of Vaccines in Cancer Immunotherapy
  3.2.1 Idiotype Cancer Vaccine Mechanism
  3.2.2 Cellular Cancer Vaccines Mechanism
  3.2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
  3.2.4 Peptide Cancer Vaccine Mechanism
  3.2.5 Tumor Host Interaction Cancer Vaccine Mechanism

4. CANCER IMMUNOTHERAPY BY MONOCLONAL ANTIBODIES

4.1 Introduction
4.2 Mechanism of Monoclonal Antibodies in Cancer Immunotherapy

5. CANCER IMMUNOTHERAPY BY ADOPTIVE CELL TRANSFER

5.1 Introduction
5.2 Mechanism of Adoptive Cell Transfer Cancer Immunotherapy

6. CANCER IMMUNOTHERAPY BY IMMUNE CHECKPOINT INHIBITORS

6.1 Introduction
6.2 Mechanism of Immune Checkpoint Inhibitors in Cancer Immunotherapy

7. CANCER IMMUNOTHERAPY BY IMMUNOMODULATORS

7.1 Introduction
7.2 Mechanism of Immunomodulators in Cancer Immunotherapy

8. CANCER IMMUNOTHERAPY BY CYTOKINES

8.1 Introduction
8.2 Mechanism of Cytokines Cancer Immunotherapy

9. CANCER IMMUNOTHERAPY BY INTERLEUKINS

9.1 Introduction
9.2 Mechanism of Interleukinsin Cancer Immunotherapy

10. CANCER IMMUNOTHERAPY BY INTERFERON

10.1 Introduction
10.2 Mechanism of Interferon Cancer Immunotherapy

11. CANCER IMMUNOTHERAPY BY GM-CSF

11.1 Introduction
11.2 Mechanism of GM-CSF Cancer Immunotherapy

12. CANCER IMMUNOTHERAPY MARKET OVERVIEW

12.1 Current Market Scenario
12.2 Cancer Immunotherapy Pipeline Overview

13. GLOBAL CANCER IMMUNOTHERAPY MARKET DYNAMICS

13.1 Favorable Market Parameters
13.2 Commercialization Challenges

14. GLOBAL CANCER IMMUNOTHERAPY MARKET FUTURE PROSPECTS

15. CANCER CELL THERAPIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

15.1 Unknown
15.2 Research
15.3 Preclinical
15.4 Clinical
15.5 Phase-I
15.6 Phase-I/II
15.7 Phase-II
15.8 Phase-III
15.9 Preregistration

16. MARKETED CANCER CELL THERAPIES DRUGS CLINICAL INSIGHT

16.1 Sipuleucel-T (Provenge®)
16.2 T-Lymphocyte Cell Therapy(Immuncell-LC®)

17. CANCER CYTOKINES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Phase-III

18. MARKETED CANCER CYTOKINES DRUGS CLINICAL INSIGHT

18.1 Aldesleukin (Proleukin®)
18.2 Denileukin Diftitox (ONTAK®)
18.3 Interferon Alpha (Multiferon®)
18.4 Interferon Alpha-2a (Roferon-A®)
18.5 Interferon Alpha-2a (Veldona®)
18.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
18.7 Interferon Alpha-2b(Intron® A)
18.8 Interferon Alpha-2b Biosimilar(Bioferon™)
18.9 Interferon Alpha-2b Biosimilar (Intalfa®)
18.10 Interferon Alpha-2b Biosimilar
18.11 Interferon-Alpha-n3 (Alferon N®)
18.12 Interferon-Beta-1b (Feron®)
18.13 Interferon-Gamma (Ogamma®)
18.14 Interleukin-2 Biosimilar (Ilcass)
18.15 Teceleukin (Imunace™)

19. CANCER IMMUNOMODULATORS CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

19.1 Unknown
19.2 Research
19.3 Preclinical
19.4 Clinical
19.5 Phase-I
19.6 Phase-I/II
19.7 Phase-II
19.8 Phase-II/III
19.9 Phase-III
19.10 Preregistration
19.11 Registered

20. MARKETED CANCER IMMUNOMODULATORS CLINICAL INSIGHT

21. CANCER VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

21.1 Research
21.2 Preclinical
21.3 Clinical
21.4 Phase-I
21.5 Phase-I/II
21.6 Phase-II
21.7 Phase-II/III
21.8 Phase-III
21.9 Preregistration
21.10 Registered

22. MARKETED CANCER VACCINES CLINICAL INSIGHT

22.1 Bladder Cancer Vaccine (PACIS®)
22.2 Bladder Cancer Vaccine
22.3 BV NSCLC
22.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
22.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
22.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
22.7 Melanoma Vaccine (MVax®)
22.8 Melanoma Vaccine (Melacine®)
22.9 Racotumomab (Vaxira®)
22.10 Sipuleucel-T (Provenge®)
22.11 Tertomotide (LucaVax)
22.12 Vitespen (Oncophage®)

23. CANCER MONOCLONAL ANTIBODIES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

23.1 Unknown
23.2 Research
23.3 Preclinical
23.4 Clinical
23.5 Phase-I
23.6 Phase-I/II
23.7 Phase-II
23.8 Phase-II/III
23.9 Phase-III
23.10 Preregistration
23.11 Registered

24. MARKETED CANCER MONOCLONAL ANTIBODIES DRUGS CLINICAL INSIGHT

25. COMPETITIVE LANDSCAPE

25.1 Abbvie
25.2 Advaxis
25.3 Altor BioScience
25.4 Amgen
25.5 Biogen Idec
25.6 Biogenomics
25.7 Celldex Therapeutics
25.8 Dendreon Corporation
25.9 Eli Lilly
25.10 Expression Genetics
25.11 Galena Biopharma
25.12 Genmab
25.13 Gilead Sciences
25.14 GlaxoSmithKline
25.15 ImmunoCellular Therapeutics
25.16 ImmunoGen
25.17 Inovio Pharmaceuticals
25.18 IRX Therapeutics
25.19 Merck
25.20 NeoStem Oncology
25.21 NewLink Genetics
25.22 Northwest Biotherapeutics
25.23 Novartis
25.24 Peregrine Pharmaceuticals
25.25 Pfizer
25.26 Philogen
25.27 Regulon
25.28 Roche
25.29 Seattle Genetics
25.30 ZymoGenetics

List Of Figures

LIST OF FIGURES

Figure 1-1: Functions of Immune System
Figure 1-2: Necessity of Cancer Immunotherapies
Figure 1-3: Benefits of Cancer Immunotherapies
Figure 2-1: Classification of Cancer Immunotherapies
Figure 2-2: Specific Cancer Immunotherapies
Figure 2-3: Non-Specific Cancer Immunotherapies
Figure 3-1: Categorization & Function of Cancer Vaccines
Figure 3-2: Classification of Different Types of Cancer vaccines
Figure 4-1: Development of Monoclonal Antibody
Figure 4-2: Principle of Monoclonal Antibodies for Cancer Immunotherapy
Figure 4-3:Type of Cancer Monoclonal Antibodies
Figure 4-4: Mechanism of Alemtuzumab
Figure 4-5: Mechanism of Ibritumomab Tiuxetan
Figure 4-6: Mechanism of Blinatumomab
Figure 5-1: Benefit of Adoptive Cell Transfer Immunotherapy
Figure 5-2: Three Adoptive Cell Transfer Strategies for Cancer Immunotherapy
Figure 5-3: Tumor-Infiltrating Lymphocytes Adoptive Cell Transfer Cancer Immunotherapy
Figure 5-4: Mechanism of CAR Modified T-Cells
Figure 5-5: Genetically Engineered TCR for Cancer Immunotherapy
Figure 6-1: Benefits of Immune Checkpoint Inhibitors
Figure 6-2:Mechanism of Ipilimumab
Figure 6-3: Mechanism of Nivolumab
Figure 6-4:Mechanism of Pembrolizumab
Figure 7-1: Functions of Immunomodulators
Figure 7-2: Benefits of Immunomodulators
Figure 7-3: Limitations of Immunomodulators
Figure 7-4: Mechanism of Thalidomide
Figure 7-5: Mechanism of Lenalidomide In Vivo
Figure 7-6: Mechanism of Lenalidomide In Vitro
Figure 7-7: Mechanism of Pomalidomide
Figure 8-1: Functions of Cytokine
Figure 8-2: Benefits of Cytokine in Cancer Immunotherapy
Figure 9-1: Functions of Interleukin
Figure 9-2: Benefits of Interleukins in Cancer Immunotherapy
Figure 9-3: Mechanism of Proleukin
Figure 9-4: Mechanism of Denileukin Diftitox
Figure 10-1: Major Types of Cytokine
Figure 10-2: Functions of Interferon
Figure 10-3: Classification of Interferons on the Basis of Types of Genes
Figure 10-4: General Mechanism of Interferons
Figure 10-5: Mechanism of Interferon Alfa-n3
Figure 10-6:Mechanism ofPeginterferon Alfa-2a
Figure 10-7: Mechanism ofInterferon Beta 1a
Figure 10-8: Mechanism of Interferon Alfa-2b
Figure 11-1: Usage of GM-CSF
Figure 11-2: Mechanism of Sargramostim
Figure 12-1: Cancer Immunotherapy Pipeline by Phase (%), 2015
Figure 12-2: Cancer Immunotherapy Pipeline by Phase (Number), 2015
Figure 12-3: Cancer Cytokines Pipeline by Phase (%), 2015
Figure 12-4: Cancer Cytokines Pipeline by Phase (Number), 2015
Figure 12-5: Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 12-6: Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
Figure 12-7: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 12-8: No Development in Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
Figure 12-9: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 12-10: Discontinued Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
Figure 12-11: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 12-12: Suspended Cancer Monoclonal Antibodies Pipeline by Phase (Number), 2015
Figure 12-13: Cancer Vaccine Pipeline by Phase (%), 2015
Figure 12-14: Cancer Vaccine Pipeline by Phase (Number), 2015
Figure 12-15: No Development Reported Cancer Vaccine Pipeline by Phase (%), 2015
Figure 12-16: No Development Reported Cancer Vaccine Pipeline by Phase (Number), 2015
Figure 12-17: Discontinued Cancer Vaccine Pipeline by Phase (%), 2015
Figure 12-18: Discontinued Cancer Vaccine Pipeline by Phase (Number), 2015
Figure 12-19: Suspended Cancer Vaccine Pipeline by Phase (%), 2015
Figure 12-20: Suspended Cancer Vaccine Pipeline by Phase (Number), 2015
Figure 12-21: Cancer Immunomodulators Pipeline by Phase (%), 2015
Figure 12-22: Cancer Immunomodulators Pipeline by Phase (Number), 2015
Figure 12-23: Cancer Cell Therapies Pipeline by Phase (%), 2015
Figure 12-24: Cancer Cell Therapies Pipeline by Phase (Number), 2015
Figure 12-25: Discontinued Cancer Cell Therapies Pipeline by Phase (%), 2015
Figure 12-26: Discontinued Cancer Cell Therapies Pipeline by Phase (Number), 2015
Figure 13 1: Favorable Cancer Immunotherapy Market Parameters
Figure 13 2: Cancer Immunotherapy Commercialization Challenges
Figure 25-1: Advaxis Clinical Pipeline
Figure 25-2: Celldex Therapeutics Clinical Pipeline
Figure 25-3: Expression Genetics Clinical Pipeline
Figure 25-4: Galena Biopharma Clinical Pipeline
Figure 25-5: ImmunoCellular Therapeutics Clinical Pipeline
Figure 25-6: ImmunoGen Clinical Pipeline
Figure 25-7: Inovio Pharmaceuticals Clinical Pipeline
Figure 25-8: NewLink Genetics Corporation Clinical Pipeline
Figure 25-9: Northwest Biotherapeutics Clinical Pipeline
Figure 25-10: Peregrine Pharmaceuticals Clinical Pipeline
Figure 25-11: Philogen Clinical Pipeline
Figure 25-12: Seattle Genetics Clinical Pipeline

List Of Tables

LIST OF TABLES

Table 4-1: Different Monoclonal Antibodies Used in Cancer Immunotherapy
Table 6-1: Some Important Checkpoint Inhibitors
Table 8-1: Few Important Immunocytokines under Clinical Development
Table 8-2: Some Pharmacologically Important Cytokines Used in Cancer Immunotherapies
Table 12-1: Few Commercially Important PD-1 Drugs